Langenbeck's Archives of Surgery

, Volume 393, Issue 5, pp 709–713 | Cite as

Serum 1-84 and 7-84 parathyroid hormone concentrations and bone in patients with primary hyperparathyroidism

  • A. Blachowicz
  • W. Chudzinski
  • I. Nawrot
  • B. Kryszalowicz
  • U. Spiechowicz
  • J. Szmidt
  • A. Wiecek
  • E. Franek
Original Article
First Online:
Received:
Accepted:

Abstract

Background and aims

Parathyroid hormone (PTH) acts on bone as both anabolic and catabolic factor. It includes two fractions: 1-84 (cyclase activating PTH, CAP) which increases bone turnover and serum calcium, and 7-84 (cyclase inactivating PTH, CIP) acting the opposite way. The aim of this study was to establish whether bone mineral density (BMD) and turnover in patients’ primary hyperparathyroidism (HPT) are dependent on CAP and CIP concentrations.

Patients/methods

Thirty-one patients with HPT and 29 appropriately matched controls were examined. Parameters of calcium-phosphate homeostasis and BMD were estimated.

Results

BMD of radius shaft was lower in patients with HPT as compared with controls, whereas BMD of spine and ultradistal radius were similar. Serum calcium, bone alkaline phosphatase, total PTH, 1-84 PTH, and 7-84 PTH were higher in HPT patients, whereas serum phosphate was lower and beta cross-laps similar. Both total PTH and CAP correlated significantly with BMD of radius shaft and serum calcium concentration, but not with other examined parameters.

Conclusion

Total and 1-84 PTH are similarly associated with examined parameters in patients with HPT. Thus, determination of serum CAP concentration does not seem to have advantages over total PTH with regard to bone mineral density and bone turnover assessment in those patients.

Keywords

Cyclase activating parathormone (1-84 PTH, CAP) Cyclase inhibiting parathormone (7-84 PTH, CIP) Primary hyperparathyroidism 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Tobias JH, Cooper C (2004) PTH/PTHrP activity and the programming of skeletal development in utero. J Bone Miner Res 19:177–182 doi: 10.1359/JBMR.0301235 PubMedCrossRefGoogle Scholar
  2. 2.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich G, Reginster JY et al (2001) Effects of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 19:1434–1441 doi: 10.1056/NEJM200105103441904 CrossRefGoogle Scholar
  3. 3.
    Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OLM, Courpron P et al (1980) Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. BMJ 280:1340–1344PubMedGoogle Scholar
  4. 4.
    Khan A, Bilezikian J (2000) Primary hyperparathyroidism: pathophysiology and impact on bone. CMAJ 163:184–187PubMedGoogle Scholar
  5. 5.
    Schmitt CP, Huber D, Mehls O, Maiwald J, Stein G, Veldhuis JD et al (1998) Altered instantaneous and Ca-modulated oscillatory PTH secretion patterns in patients with secondary hyperparathyroidism. J Am Soc Nephrol 9:1832–1844PubMedGoogle Scholar
  6. 6.
    Harms HM, Kaptaina U, Külpmann WR, Brabant G, Hesch RD (1989) Pulse amplitude and frequency modulation of parathyroid hormone in plasma. J Clin Endocrinol Metab 69:843–851PubMedCrossRefGoogle Scholar
  7. 7.
    Hock JM, Gera I (1992) Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7:65–72PubMedCrossRefGoogle Scholar
  8. 8.
    Qin L, Raggatt LJ, Partridge NC (2004) Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab 15(2):60–65 doi: 10.1016/j.tem.2004.01.006 PubMedCrossRefGoogle Scholar
  9. 9.
    Dai JC, He P, Chen X, Greenfield EM (2006) TNF alpha and PTH utilize distinct mechanism to induce IL-6 and RANKL expression with markedly different kinetics. Bone 38:509–520 doi: 10.1016/j.bone.2005.10.007 PubMedCrossRefGoogle Scholar
  10. 10.
    Gao P, Scheibel S, D’Amour P, John MR, Rao SD, Schmidt-Gayk H, Cantor TL (2001) Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16:605–614 doi: 10.1359/jbmr.2001.16.4.605 PubMedCrossRefGoogle Scholar
  11. 11.
    Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G et al (2000) A novel mechanism for skeletal resistance in uremia. Kidney Int 58:753–761 doi: 10.1046/j.1523-1755.2000.00222.x PubMedCrossRefGoogle Scholar
  12. 12.
    Sneddon WB, Yang Y, Ba J, Harinstein L, Friedman PA (2007) Extracellular signal-regulated kinase activation by parathyroid hormone in distal tube cells. Am J Physiol Renal Physiol 292:F1028–F1034PubMedCrossRefGoogle Scholar
  13. 13.
    Huan J, Olgaard K, Nielsen LB, Lewin E (2006) Parathyroid hormone 7-84 induces hypocalcemia and inhibits the parathyroid hormone 1-84 response to hypocalcemia in rats with intact parathyroid glands. J Am Soc Nephrol 17(7):1923–1930 doi: 10.1681/ASN.2005101136 PubMedCrossRefGoogle Scholar
  14. 14.
    Monier-Faugere HC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL et al (2001) Improved assessment of bone turnover by the PTH- (1-84) large C-PTH fragments ratio in ESRD patients. Kidney Int 60:1460–1468 doi: 10.1046/j.1523-1755.2001.00949.x PubMedCrossRefGoogle Scholar
  15. 15.
    Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai GA et al (2002) PTH 1-84 and PTH “7-84” in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 40:348–354 doi: 10.1053/ajkd.2002.34519 PubMedCrossRefGoogle Scholar
  16. 16.
    Reichel H, Esser A, Roth HJ, Schmidt-Gayk H (2003) Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 18:759–768 doi: 10.1093/ndt/gfg144 PubMedCrossRefGoogle Scholar
  17. 17.
    Roth HJ, Albert C, Schmidt-Gayk H (2002) New assays for intact parathormone and their clinical relevance for the diagnosis of hyperparathyroidism. Clin Lab (Zaragoza) 48:589–593Google Scholar
  18. 18.
    www.scantibodies.com, entry on April 29th, 2008
  19. 19.
    Silverberg SJ, Bilezikian JP (1996) Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 81:2036–2040 doi: 10.1210/jc.81.6.2036 PubMedCrossRefGoogle Scholar
  20. 20.
    Samuels MH, Veldhuis JD, Kramer P, Urban JR, Bauer R, Mundy GR (1997) Episodic secretion of parathyroid hormone in postmenopausal women: assessment of deconvolution analysis and approximate entropy. J Bone Miner Res 12:616–623 doi: 10.1359/jbmr.1997.12.4.616 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • A. Blachowicz
    • 1
  • W. Chudzinski
    • 2
  • I. Nawrot
    • 2
  • B. Kryszalowicz
    • 1
  • U. Spiechowicz
    • 3
  • J. Szmidt
    • 2
  • A. Wiecek
    • 3
  • E. Franek
    • 1
    • 4
    • 5
  1. 1.Department of Internal Diseases, Endocrinology and DiabetologyCentral Clinical Hospital MSWiAWarsawPoland
  2. 2.Department of General, Vascular and Transplant SurgeryWarsaw Medical UniversityWarsawPoland
  3. 3.Department of Nephrology, Endocrinology and Metabolic DiseasesMedical University of SilesiaKatowicePoland
  4. 4.Department of EndocrinologyMedical Research Center of Polish Academy of SciencesWarsawPoland
  5. 5.Department of Internal Medicine, Endocrinology and DiabetologyCentral Clinical Hospital MSWiAWarszawaPoland

Personalised recommendations